Nothing Special   »   [go: up one dir, main page]

MA47575A - Composés inhibiteurs d'oga monocyclique - Google Patents

Composés inhibiteurs d'oga monocyclique

Info

Publication number
MA47575A
MA47575A MA047575A MA47575A MA47575A MA 47575 A MA47575 A MA 47575A MA 047575 A MA047575 A MA 047575A MA 47575 A MA47575 A MA 47575A MA 47575 A MA47575 A MA 47575A
Authority
MA
Morocco
Prior art keywords
monocyclic
inhibitor compounds
oga inhibitor
oga
compounds
Prior art date
Application number
MA047575A
Other languages
English (en)
Inventor
Manuel Jésus Alcázar-Vaca
José Manuel Bartolomé-Nebreda
Gang Chen
Viturro Carlos Manuel Martinez
Andrés Avelino Trabanco-Suárez
Gary John Tresadern
Wei Zhang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA47575A publication Critical patent/MA47575A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA047575A 2016-12-16 2017-12-15 Composés inhibiteurs d'oga monocyclique MA47575A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16204840 2016-12-16

Publications (1)

Publication Number Publication Date
MA47575A true MA47575A (fr) 2020-01-01

Family

ID=57570524

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047575A MA47575A (fr) 2016-12-16 2017-12-15 Composés inhibiteurs d'oga monocyclique

Country Status (8)

Country Link
US (1) US20200079766A1 (fr)
EP (1) EP3555087A1 (fr)
JP (1) JP2020503298A (fr)
CN (1) CN110300752A (fr)
AU (1) AU2017378186A1 (fr)
CA (1) CA3045957A1 (fr)
MA (1) MA47575A (fr)
WO (1) WO2018109202A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015308437C1 (en) 2014-08-28 2020-11-05 Asceneuron Sa Glycosidase inhibitors
MA43680A (fr) 2016-02-25 2018-11-28 Asceneuron Sa Inhibiteurs de glycosidases
AU2017222958B2 (en) 2016-02-25 2019-07-18 Asceneuron S. A. Glycosidase inhibitors
CN109071526B (zh) 2016-02-25 2023-02-28 阿森纽荣股份公司 哌嗪衍生物的酸加成盐
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
AR110747A1 (es) * 2017-01-27 2019-05-02 Lilly Co Eli Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
MA47591A (fr) * 2017-02-27 2020-01-01 Janssen Pharmaceutica Nv Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga
EP3672959A1 (fr) 2017-08-24 2020-07-01 Asceneuron SA Inhibiteurs linéaires de la glycosidase
US11459324B2 (en) 2018-03-14 2022-10-04 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors
MX2020009530A (es) * 2018-03-14 2021-01-15 Biogen Ma Inc Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
CA3102462A1 (fr) * 2018-06-20 2019-12-26 Janssen Pharmaceutica Nv Composes inhibiteurs d'oga
US20210300900A1 (en) * 2018-06-20 2021-09-30 Janssen Pharmaceutica Nv Oga inhibitor compounds
US20210261527A1 (en) * 2018-06-20 2021-08-26 Janssen Pharmaceutica Nv Oga inhibitor compounds
US20210122763A1 (en) * 2018-06-20 2021-04-29 Janssen Pharmaceutica Nv Oga inhibitor compounds
US11999726B2 (en) 2018-07-31 2024-06-04 Eli Lilly And Company 5-methyl-4-fluoro-thiazol-2-yl compounds
WO2020039028A1 (fr) 2018-08-22 2020-02-27 Asceneuron S. A. Inhibiteurs de tétrahydro-benzoazépine glycosidase
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
WO2020039029A1 (fr) 2018-08-22 2020-02-27 Asceneuron S. A. Composés spiro utilisés en tant qu'inhibiteurs de glycosidases
SG11202102379XA (en) * 2018-09-19 2021-04-29 Biogen Ma Inc O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
TWI716107B (zh) * 2018-09-26 2021-01-11 美商美國禮來大藥廠 6-氟-2-甲基苯并[d]噻唑-5-基化合物
EP3891146B1 (fr) * 2018-12-05 2023-09-27 Biogen MA Inc. Dérivés morpholinyle, pipérazinyle, oxazépanyle et diazépanyle en tant qu'inhibiteurs de o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
US20220106305A1 (en) * 2019-02-04 2022-04-07 Biogen Ma Inc. Bicyclic ether o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
US20220259197A1 (en) * 2019-03-08 2022-08-18 Biogen Ma Inc. Azetidinyl o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
AR120406A1 (es) 2019-11-06 2022-02-09 Yuhan Corp Compuestos de pirrolidina y piperidina
WO2021094312A1 (fr) 2019-11-11 2021-05-20 Janssen Pharmaceutica Nv Composés inhibiteurs d'oga contenant de la pyrrolidine et de la bicyclohétéroaryle
KR102533471B1 (ko) * 2020-11-23 2023-05-19 (주) 메디프론디비티 O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도
WO2024081775A1 (fr) 2022-10-14 2024-04-18 Eli Lilly And Company Synthèse de composés 6-fluoro-2-méthylbenzo[d] thiazol-5-yle

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1595923A1 (de) * 1965-02-20 1969-11-27 Merck Ag E 1-Aralkyl-4-(thiazolyl-2)-piperazine und Verfahren zu ihrer Herstellung
EP0636130A1 (fr) 1992-04-15 1995-02-01 Merck Sharp & Dohme Ltd. Composes azacycliques
US6982259B2 (en) 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
KR20080111015A (ko) 2006-03-31 2008-12-22 아스트라제네카 아베 비시클릭 벤즈이미다졸 화합물 및 대사성 글루타메이트 수용체 증강체로서 이들의 용도
WO2008012623A1 (fr) 2006-07-25 2008-01-31 Pfizer Products Inc. Composés de benzimidazolyle constituant des potentialisateurs du sous-type de récepteur de glutamate mglur2
GB201103526D0 (en) 2011-03-02 2011-04-13 Summit Corp Plc Selective glycosidase inhibitors and uses thereof
ES2723883T3 (es) * 2013-03-14 2019-09-03 Merck Patent Gmbh Inhibidores de glicosidasa
AU2015308437C1 (en) * 2014-08-28 2020-11-05 Asceneuron Sa Glycosidase inhibitors
WO2017106254A1 (fr) 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Inhibiteurs de glycosidase et leurs utilisations
MA43680A (fr) 2016-02-25 2018-11-28 Asceneuron Sa Inhibiteurs de glycosidases
CN109071526B (zh) 2016-02-25 2023-02-28 阿森纽荣股份公司 哌嗪衍生物的酸加成盐
AU2017222958B2 (en) 2016-02-25 2019-07-18 Asceneuron S. A. Glycosidase inhibitors

Also Published As

Publication number Publication date
CA3045957A1 (fr) 2018-06-21
EP3555087A1 (fr) 2019-10-23
JP2020503298A (ja) 2020-01-30
WO2018109202A1 (fr) 2018-06-21
CN110300752A (zh) 2019-10-01
US20200079766A1 (en) 2020-03-12
AU2017378186A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
MA47575A (fr) Composés inhibiteurs d'oga monocyclique
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
MA52942A (fr) Composés inhibiteurs d'oga
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
MA52939A (fr) Composés inhibiteurs d'oga
MA47420A (fr) Composés inhibiteurs d'oga
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
MA44725A (fr) Formulations d'un inhibiteur de lsd1
DK3442972T3 (da) Bromdomænehæmmere
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
DK4039675T3 (da) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
MA41169A (fr) Composés antibactériens à large spectre d'activité
MA50906A (fr) Inhibiteurs d'immunoprotéasome
MA49006A (fr) Inhibiteurs d'ip6k
DK3737677T3 (da) Tetrahydroisoquinolinforbindelser
DK3562487T3 (da) Metalloenzyminhibitorforbindelser
MA52935A (fr) Composés inhibiteurs d'oga
DK3485004T3 (da) Malatdehyrogenaser
LU92414B1 (fr) Compostion cosmétique anhydre applicable sur les ongles
FI20160183L (fi) Parannettu puolijohdekokoonpano
DK3672941T3 (da) Pyridylpyridonforbindelser
DK3481826T3 (da) Tyrosinkinaseinhibitorer
MA52936A (fr) Composés inhibiteurs d'oga
MA52937A (fr) Composés inhibiteurs d'oga